Oncotarget

Research Papers:

EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN

Zhaoming Li, Ran Qiu, Xia Qiu and Tian Tian _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:110837-110848. https://doi.org/10.18632/oncotarget.22860

Metrics: PDF 543 views  |   HTML 1062 views  |   ?  


Abstract

Zhaoming Li1, Ran Qiu2, Xia Qiu3 and Tian Tian4

1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

2Wuhan Institute of Bioengineering, Wuhan, China

3Department of Medicine, Shangqiu Medical School, Shangqiu, China

4Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Correspondence to:

Tian Tian, email: zhaomingli2008@hotmail.com

Keywords: EYA2; PTEN; lung cancer; cell proliferation; prognosis

Received: September 04, 2017     Accepted: October 29, 2017     Published: December 02, 2017

ABSTRACT

Lung cancer is the leading cause of cancer-related death worldwide. Despite advances have been made in diagnosis and therapeutic strategies, the prognosis of lung cancer is still very poor. Eyes absent transcriptional cofactor EYA2 has been shown to promote lung cancer cell growth, however, the underlying molecular mechanism is still not fully understood. In the present study, we found that EYA2 was up-regulated in lung cancer, and EYA2 led to increased cell proliferation by inhibiting Phosphatase and tensin homologue (PTEN) expression via modulation of miR-93. Additionally, survival analysis showed that lung cancer patients with higher EYA2 expression predicted a worse prognosis. Therefore, these findings demonstrate that EYA2 may play an important role in lung cancer occurrence and progression. Targeting EYA2 may provide a feasible approach in developing novel anticancer therapeutics.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22860